Triple combination superior to double combination.
Patients taking a triple combination of AZT, ddI, and nevirapine appear to have better surrogate markers than those taking the double combination of AZT and ddI, according to 241 AIDS Clinical Trials Group (ACTG) researchers. The triple combination resulted in a 40 percent increase in T-cells over baseline, which persisted through 40 weeks of the study. The triple combination also produced greater decreases in the viral load. Although the trial was not designed to evaluate clinical endpoints, there appeared to be no difference in clinical endpoints except in patients with fewer than 50 T-cells or where there was a trend toward fewer clinical endpoints with the triple combination. Nevirapine, an investigational nonnucleoside reverse transcriptase, is available only through clinical trials.
Grodeck
B
B
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine; D016047:Zalcitabine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
D000998:Antiviral Agents; D015415:Biomarkers; D019259:Lamivudine; D015215:Zidovudine; D016047:Zalcitabine